v3.26.1
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2026
Jun. 30, 2026
Sep. 30, 2025
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Cost of sales   $ 4,395   $ 3,557 $ 8,590 $ 6,976  
Selling, general and administrative   2,904   2,649 5,604 5,202  
Research and development   9,741   4,048 22,333 7,669  
Other current assets   36,679     36,679   $ 43,516
Accrued and other current liabilities   14,725     14,725   14,468
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenue from collaborative arrangement   375   413 877 769  
Cost of sales   84   86 169 169  
Selling, general and administrative   25   40 49 72  
Research and development   9   16 15 28  
Other current assets   375     375   451
Other assets   125     125   125
Accrued and other current liabilities   6     6   $ 6
Upfront payments recognized as revenue         150    
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenue from collaborative arrangement   365   370 706 682  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Revenue from collaborative arrangement   $ 10   $ 43 $ 171 $ 87  
Upfront payments recognized as revenue $ 150   $ 150